Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas

SC142-reactive antigen are highly glycosylated glycoproteins expressed on tissues of gastric and colon cancers but not on normal tissues. Murine SC142 antibody specific for the SC142-reactive antigen has been produced by immunisation with SNU16 stomach cancer cells. However, SC142 antibody has several potential problems such as high immunogenicity and poor tumour penetration owing to their large size. To improve tumour penetration potential in vivo, recombinant single-chain fragments have been produced using the original hybridoma cells as a source of variable heavy- and variable light-chain-encoding antibody genes. The use of the polymerase chain reaction, expression cloning technology and gene expression systems in E. coli has led to the production of SC142 single-chain fragments, which was similar in activity to the SC142 parent antibody confirmed by immunohistochemistry. Analysis by DNA sequencing, SDS–PAGE and Western blotting has demonstrated the integrity of the single-chain fragments. Competitive ELISA showed that SC142 single-chain fragments originated from parent SC142 antibody. BIAcore biosensor binding experiments showed that the SC142 single-chain fragments had an ideal dissociation rate constant as a tumour imaging reagent. These results illustrate the potential application of these novel products as an immunodiagnostic and further immunotherapeutic reagent.

[1]  K. Tsumoto,et al.  Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent--application to a human single-chain Fv fragment. , 1998, Journal of immunological methods.

[2]  P. Suh,et al.  Expression and characterization of anti-NCA-95 scFv (CEA 79 scFv) in a prokaryotic expression vector modified to contain a Sfi I and Not I site. , 1999, Hybridoma.

[3]  T. Goi,et al.  Expression of nm23-H1 Gene and Sialyl Lewis X Antigen in Breast Cancer , 1998, Oncology.

[4]  E. Nice,et al.  Determination of relative binding affinity of influenza virus N9 sialidases with the Fab fragment of monoclonal antibody NC41 using biosensor technology. , 1993, European journal of biochemistry.

[5]  P. Wirsching,et al.  Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Rhodes,et al.  Purification and characterization of a peanut‐agglutinin‐binding pancreatic‐cancer‐related serum mucus glycoprotein , 1990, International journal of cancer.

[7]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[8]  Andrew M. Scott,et al.  Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector , 2001, Cancer Immunology, Immunotherapy.

[9]  H. Hewitt,et al.  A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. , 1976, British Journal of Cancer.

[10]  K. D. Hardman,et al.  Immunological and structural characterization of a high affinity anti-fluorescein single-chain antibody. , 1990, Journal of Biological Chemistry.

[11]  B. Groner,et al.  Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. , 1992, Cancer research.

[12]  H. Denley,et al.  Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas. , 1997, British Journal of Cancer.

[13]  B. Davidson,et al.  Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  M. Verma,et al.  Mucin genes: structure, expression and regulation , 1994, Glycoconjugate Journal.

[15]  P. Correa,et al.  A human model of gastric carcinogenesis. , 1988, Cancer research.

[16]  K. D. Hardman,et al.  Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli. , 1991, Biochemistry.

[17]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[18]  César Milstein,et al.  Man-made antibodies , 1991, Nature.

[19]  M. Clark,et al.  Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.

[20]  J. M. Creeth,et al.  The use of equilibrium-density-gradient methods for the preparation and characterization of blood-group-specific glycoproteins. , 1970, The Biochemical journal.

[21]  L. Wysocki,et al.  Sequence heterogeneity in Ig kappa transcripts from single B lymphocytes. , 2000, Molecular immunology.

[22]  H. Hoogenboom,et al.  Creating and engineering human antibodies for immunotherapy. , 1998, Advanced drug delivery reviews.

[23]  M. Lan,et al.  Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. , 1985, Cancer Research.